comprehensive -WSS

comprehensive

author：entertainment 2025-08-20 09:37:24 - browse：84112

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In age of alternative facts, a scholarly course on calling out crap
Next article： Can CDC director Mandy Cohen drive consensus in Washington?

WSS

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Everything to know for the next Powerball drawing as jackpot hits $1 billion

Researchers tackle phage therapy hurdles for wider adoption

Congress likely to miss an opportunity to fix drug shortages issue

Flagship Pioneering startup Sonata Therapeutics lays off 21

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

focus

comprehensive

focus

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Congress: Eradicate hepatitis C and reduce the deficit

In age of alternative facts, a scholarly course on calling out crap

Researchers tackle phage therapy hurdles for wider adoption

23andMe had bad news about my health. I wish a person had delivered it

Federal judge rules Oregon’s tough new gun law is constitutional

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Apple is now the first public company to be valued at $3 trillion

Opioid cravings were reduced by anti

leisure time

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Congress likely to miss an opportunity to fix drug shortages issue

Eli Lilly to acquire Versanis in heated race for weight loss drugs

A new drug could help frostbite victims avoid its ravages

Blood tests recalled over risk of missed heart attack diagnosis

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

explore

entertainment

explore

leisure time